The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial.
options for patients with metastatic melanoma [1] . However, several effective new treatment options, including immunotherapy (anti-CTLA-4 and anti PD-1) and targeted therapy (BRAF and MEK inhibitors) for patients with BRAF-mutated melanoma have recently been approved by the FDA [2] [3] [4] [5] [6] [7] [8] . Despite these therapeutic advances, chemotherapy retains a role in the treatment of patients with metastatic melanoma, including those without a targetable mutation [9] . However, neither single agents [10, 11] nor combination chemotherapy regimens [12] have demonstrated a clear advantage over dacarbazine alone, and improved therapeutic options are needed.
Although taxanes have shown limited efficacy in metastatic melanoma [11, [13] [14] [15] [16] [17] , paclitaxel formulated as albumin-bound nanoparticles [nab-paclitaxel (Abraxane); Celgene, Summit, New Jersey] demonstrated a promising response rate (21.6%), median progression-free survival (PFS) of 4.5 months, and median overall survival (OS) of 9.6 months in a phase II study of chemotherapy-naïve patients [18] . Based on the promising utility of nab-paclitaxel in metastatic melanoma, this phase III study compared the efficacy and safety of single-agent nabpaclitaxel versus dacarbazine in chemotherapy-naïve patients.
patients and methods
This study was approved by the independent ethics committees of the participating medical institutions and was conducted in compliance with the protocol, the World Medical Association Declaration of Helsinki, Good Clinical Practice, and the Guidelines of the International Conference on Harmonization [19] . Written informed consent was obtained from all patients before study initiation.
patients
Adults with histologically/cytologically confirmed stage IV malignant melanoma were eligible if they had received no prior cytotoxic therapy and had ≥1 radiographically measurable lesion, based on Response Evaluation Criteria in Solid Tumor (RECIST) v1.0 [20] . Previous treatments with kinase inhibitors or cytokines were permitted if they were completed 4 weeks before enrollment. Patients with history of in situ, basal, or squamous cell skin cancer were eligible. Patients with other malignancies were also eligible if they were cured by surgery and/or radiation and had been continuously disease free for ≥5 years. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, a life expectancy of >12 weeks, and lactate dehydrogenase (LDH) levels ≤2× the upper limit of normal (ULN) were eligible. Patients were excluded from the study if they had prior/ current brain metastases.
study design
In this open-label, multicenter phase III study, eligible patients were randomized 1 : 1 via a centralized system to nab-paclitaxel 150 mg/m 2 
assessment of efficacy and safety end points
Patients were evaluated for response and progression using RECIST criteria v1.0. Radiographic evaluation by computed tomography scan was carried out at baseline (within 7 days of starting treatment) and then every 8 weeks in both arms. Safety and tolerability were monitored through reporting of adverse events (AEs), serious AEs (SAEs), laboratory abnormalities, and incidence of patients experiencing dose modifications and/or premature discontinuation of study drug.
end points and statistical methods
The primary efficacy end point was PFS based on an independent radiological review and the secondary efficacy end point was OS; both were summarized by median time [including 95% confidence interval (CI)] for each treatment arm along with the hazard ratio (HR, including 95.1% CI for PFS and 99.9% CI for OS). The differences in Kaplan-Meier curves were tested using stratified log-rank test. The summary of censoring is described in the CONSORT diagram (supplementary Figure S1 , available at Annals of Oncology online). All randomized patients were evaluated for efficacy [intent-to-treat exploratory biomarker analyses SPARC immunohistochemistry (IHC) was carried out and scored as previously described (see supplementary Materials, available at Annals of Oncology online) [22] . H&E stained slides were scored for tumor-infiltrating lymphocytes and the score was correlated with survival outcomes (see supplementary Materials, available at Annals of Oncology online). Figure S1 , available at Annals of Oncology online). The two treatment arms were generally well balanced for relevant baseline characteristics (Table 1) . Only 8% of patients received prior therapy for metastatic disease, such as immunostimulants (6%) and antineoplastic agents (2%), including kinase inhibitors.
efficacy results
progression-free survival. In the final PFS analysis, 152 patients (58%) in the nab-paclitaxel and 170 patients (64%) in the dacarbazine arm had progressed or died. Median PFS was 4.8 and 2.5 months, respectively (HR, 0.792; 95.1% CI 0.631-0.992; P = 0.044; Figure 1A ; Table 2 ). The PFS estimate at 6 months was 37% with nab-paclitaxel versus 30% with dacarbazine. The robustness of the PFS analysis was supported with various sensitivity analyses related to off-schedule response assessments Figure 1B ; Table 2 ). Most (75%) patients received subsequent therapies (77% nabpaclitaxel; 73% dacarbazine): 13% and 10% of patients received a BRAF inhibitor, and 31% and 32% received ipilimumab, in the nab-paclitaxel and dacarbazine arms, respectively. Additionally, 15% and 11% of patients received other immunotherapy or targeted therapy, 18% and 23% of patients received subsequent chemotherapy (other than nab-paclitaxel-based therapy), and 25% and 22% of patients received radiotherapy in the nab-paclitaxel and dacarbazine arms, respectively. The median time to the start of poststudy therapy was 26 and 21 days, respectively. overall response and disease control rates. Independently assessed ORR was 15% versus 11% (response rate ratio, 1.305; 95% CI 0.837-2.035; P = 0.239) with nab-paclitaxel versus dacarbazine (Table 2 ). For patients who had a confirmed CR or PR, the median time to response was 2.2 versus 3.6 months, respectively (P = 0.44). Treatment with nab-paclitaxel versus dacarbazine resulted in a significant improvement in DCR (P = 0.004) and best ORR (P = 0.002; Table 2 ). Significantly less progressive disease was observed with nab-paclitaxel (35%) versus dacarbazine (48%), P = 0.005.
analyses by subgroups. In general, most subgroup analyses indicated an improvement in favor of the nab-paclitaxel arm ( Figure 2 ). Improvement in PFS with nab-paclitaxel occurred in all patients regardless of age, region, baseline LDH, BRAF mutation status, and patients with M1c/poor prognosis. Of note, nabpaclitaxel produced longer PFS (HR, 0.734; 95% CI 0.558-0.965; P = 0.028) compared with dacarbazine for patients with the most advanced melanoma (M1c). Trends toward longer PFS favoring nab-paclitaxel were observed in all BRAF subgroups (Table 2) .
treatment exposure and dose reductions
The median treatment duration was 11.1 weeks for nab-paclitaxel and 6.4 weeks for dacarbazine. The median number of cycles was 3 in each arm. Median percentage of protocol dose was 98% (min, max: 50%, 105%) and 100% (min, max: 48%, 105%) in the nab-paclitaxel and dacarbazine arms, respectively. Median dose intensity was 146.5 and 333.3 mg/m 2 /week, respectively, noting that dacarbazine was given every 3 weeks. More dose reductions occurred with nab-paclitaxel (32%) versus dacarbazine (20%), all of which were due to AEs, mainly neuropathy.
safety results
Both agents produced expected AE profiles (Table 3) . Specifically, 50% versus 27% of patients had ≥1 treatmentrelated AE (TRAE) and 9% versus 7% patients had ≥1 treatment-related SAE in the nab-paclitaxel arm versus dacarbazine arm, respectively. The most common grade ≥3 TRAEs were neuropathy (25% versus 0%), neutropenia (20% versus 10%), and leukopenia (12% versus 7%) in the nab-paclitaxel versus dacarbazine arm, respectively (Table 3) . No patients experienced grade ≥3 thrombocytopenia during treatment with nab-paclitaxel compared with 6% of patients receiving dacarbazine. Of the grade ≥3 treatment-related peripheral neuropathy events, all occurred in the nab-paclitaxel arm; 2 events were grade 4. The median onset of grade ≥3 peripheral neuropathy was 101 days (95% CI 85-113) after start of treatment. After treatment modification, median times for grade ≥3 peripheral neuropathy to improve by ≥1 grade and to reduce to grade ≤1 were 28 and 67 days, respectively. Thirty-two percent of patients never developed treatment-related neuropathy in the nab-paclitaxel arm. SPARC IHC data were evaluable in 194 patient tumor samples (100 for nab-paclitaxel and 94 for dacarbazine). Baseline characteristics for this patient subset were similar to the ITT population. Patients were classified into high SPARC (n = 53 for nab-paclitaxel; n = 50 for dacarbazine) or low SPARC (n = 47 for nab-paclitaxel; n = 44 for dacarbazine). Independently assessed PFS was similar between patients with high SPARC and low SPARC scores who were in the nab-paclitaxel (median PFS 3.71 versus 3.94 months; P = 0.783) or dacarbazine (median PFS 3.71 versus 1.91 months; P = 0.182) arms.
Results from a post hoc analysis of TILs are reported in the supplementary Materials, available at Annals of Oncology online. discussion nab-Paclitaxel demonstrated clinically meaningful superiority compared with dacarbazine, with a near doubling of median PFS and a 44% improvement in DCR (includes patients with SD for ≥16 weeks) in chemotherapy-naïve patients with metastatic melanoma. Compared with dacarbazine, nab-paclitaxel reduced the risk of disease progression or death by >20%. The results observed for dacarbazine in this study were consistent with recent phase III trials [3-5, 8, 10, 11] . Early separation of the survival curves at 3 months provided evidence of early treatment effect, which was maintained for more than 30 months. Although a significant difference in PFS was observed with nab-paclitaxel versus dacarbazine, a significant treatment effect of nab-paclitaxel on SPARC, an albumin-binding protein, has both protumorigenic and antitumorigenic properties [23] . SPARC expression may be associated with positive clinical outcomes in patients receiving nab-paclitaxel, as it may help to enrich nab-paclitaxel in the tumor and/or tumor microenvironment (reviewed in Yardley) [24] . However, no correlation was found between tumor SPARC expression and PFS with nab-paclitaxel treatment in this trial. A recent analysis of a large phase III trial of metastatic pancreatic cancer similarly found no correlation between SPARC expression, nab-paclitaxel treatment, and clinical outcome [25] .
All AEs were manageable, and no new or unexpected AEs were noted for nab-paclitaxel in patients with metastatic melanoma [26] [27] [28] . Grade ≥3 treatment-related peripheral neuropathy was seen only in patients receiving nab-paclitaxel and was consistent with the incidence observed in patients receiving the agent for the approved indications [26] [27] [28] . Peripheral neuropathy was the primary reason for the higher rate of treatment discontinuation in the nab-paclitaxel arm than in the dacarbazine arm. Despite the high rate of grade ≥3 peripheral neuropathy, a number of patients were able to resume treatment with nab-paclitaxel following dose modification procedures that improved peripheral neuropathy by at least 1 grade in half the patients within 1 month. Thus, neuropathy management with treatment modifications remains important for patients to be able to receive the maximum benefit from nab-paclitaxel. Other strategies may include using drugs such as pregabalin or duloxetine, which may ameliorate chemotherapy-induced peripheral neuropathy [29] .
One limitation of this study was that patients with >2× ULN of LDH were excluded; however, attempts were made to mirror the general population within the LDH categories. It has been established that exceedingly high levels of LDH may also make melanoma cells resistant to certain treatments [30] . Collection of quality-of-life data may have helped to more fully assess the clinical benefit of nab-paclitaxel in this patient population.
The higher efficacy observed for nab-paclitaxel versus historical trials of sb-paclitaxel in metastatic melanoma [15] [16] [17] may be explained by the intrinsic benefit of albumin-based nab technology and its distinct pharmacokinetic profile versus sb-paclitaxel [31] . The lack of solvent, which alone contributes to neuropathy [32] and hypersensitivity reactions [33] , may contribute to an improved tolerability profile and allow for higher dose delivery and intensity of nab-paclitaxel compared with sb-paclitaxel [26, 27] . Efficacy results with single-agent nab-paclitaxel in our study compared favorably with the commonly used regimen of sb-paclitaxel plus carboplatin reported in a phase III study of patients with metastatic melanoma, producing similar efficacy outcomes (18% ORR; median PFS and OS of 4.2 and 11.3 months, respectively) [34] . Neutropenia, leukopenia, and sensory neuropathy were the most common grade ≥3 TRAEs observed with sb-paclitaxel plus carboplatin in that study. In a recent phase II study, nab-paclitaxel plus bevacizumab as first-line therapy in patients with metastatic melanoma produced a 36% ORR and a median PFS and OS of 7.6 and 16.8 months, respectively [35] , suggesting that nab-paclitaxel may synergize with other therapeutics, including immunotherapy, and should be further explored in clinical trials. A phase II trial is underway to study nab-paclitaxel in combination with ipilimumab (NCT01827111) in patients with advanced or metastatic melanoma [36] . Chemotherapy remains an important treatment option for patients with BRAF wild-type melanoma who are not candidates for ipilimumab and patients with BRAF mutant disease resistant to BRAF inhibitors [9] . In the present trial, nab-paclitaxel benefited patients regardless of BRAF mutation status. Additionally, in a post hoc analysis of this trial, nab-paclitaxel was shown to benefit a subgroup of patients with low or absent TILs (see supplementary Materials, available at Annals of Oncology online), a poor prognostic factor in melanoma [37] .
In conclusion, nab-paclitaxel demonstrated a clinical benefit versus dacarbazine and produced a manageable safety profile. Thus, nab-paclitaxel can be considered in the treatment armamentarium for chemotherapy-naïve patients with metastatic melanoma. The National Comprehensive Cancer Network guidelines recommend nab-paclitaxel as a single agent for the treatment of advanced or metastatic melanoma (category 2A) [38] . Results of ongoing trials of nab-paclitaxel in combination with targeted therapies or novel immunotherapies may help expand this recommendation in the future, as nab-paclitaxel may provide a good backbone regimen to build upon given its safety profile.
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